Skip to main content
TipRanks
Go Ultimate75% OFF

Geratherm Medical (GME) AI Stock Analysis

10 Followers
DE:GME

Geratherm Medical

(XETRA:GME)

Select Model
Rating:51Neutral
Price Target:EUR 2.00â–¼(-2.91% Downside)
Action:reiterated
Date:11/14/26

Overall score reflects weakening operating performance (losses and volatile/weak revenue) despite a conservative balance sheet and still-positive (but declining) free cash flow. Technicals add pressure as the price is below key moving averages with a negative MACD, while valuation is supported mainly by the ~5% dividend yield.

Positive Factors
Conservative balance sheetLow leverage and substantial equity relative to assets provide financial flexibility during operating volatility. This can reduce financing pressure, preserve capacity to fund product development or distribution, and improve resilience over the next several quarters.
Negative Factors
Sharp revenue contractionThe reported revenue contraction points to weakened demand, channel performance, or product contribution and makes the earnings base less dependable. Sustained top-line pressure could reduce operating leverage, limit investment capacity, and make a return to profitability more difficult.

Geratherm Medical (GME) vs. iShares MSCI Germany ETF (EWG)

-40%-30%-20%-10%0%10%20%DE:GME-36.54%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.22M
Dividend Yield
4.85%
Average Volume (3M)
1,106
Price to Earnings (P/E)
-14.8
Beta (1Y)
0.52
Revenue Growth
1.58%
EPS Growth
-148.73%
Country
Germany
Employees
136
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Geratherm Medical Business Overview & Revenue Model

Company Description

Geratherm Medical AG, a German-based medical technology enterprise, organizes its operations across four primary divisions: Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems. The Healthcare Diagnostic unit offers a range...

How the Company Makes Money

Geratherm Medical makes money primarily by selling medical devices and associated health products to distributors, pharmacies, retailers, and other healthcare-channel customers. Revenue is generated through (1) product sales of Geratherm-branded meas...

Geratherm Medical Financial Statement Overview

Summary

Financials are mixed. The balance sheet is a strength with low leverage (TTM debt-to-equity ~0.11) and solid equity vs. assets, but profitability has deteriorated back into losses (TTM net margin ~-5.8%) alongside sharply negative reported revenue growth (-219%). Cash flow is positive (TTM FCF ~€0.4m) but weakening (FCF growth ~-46%) and conversion is uneven.

Income Statement

38Negative

Balance Sheet

72Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue14.70M14.86M20.43M20.96M25.85M24.64M
Gross Profit9.82M2.37M12.78M6.27M6.38M16.32M
EBITDA217.53K-154.63K2.95M4.20M3.37M2.20M
Net Income-854.16K-818.99K705.17K1.11M1.02M122.23K
Balance Sheet
Total Assets25.54M26.00M28.54M35.72M38.38M34.56M
Cash, Cash Equivalents and Short-Term Investments8.81M9.26M9.64M7.74M10.89M6.47M
Total Debt2.19M2.48M3.28M7.23M9.29M9.32M
Total Liabilities6.62M6.55M7.71M13.11M16.15M15.93M
Stockholders Equity19.38M19.66M21.02M22.33M22.34M18.52M
Cash Flow
Free Cash Flow419.00K1.22M1.23M-212.00K-133.00K-353.00K
Operating Cash Flow618.00K1.39M1.87M1.43M2.61M917.00K
Investing Cash Flow-532.00K-328.00K3.82M-2.09M-767.00K3,000
Financing Cash Flow-1.24M-1.31M-2.69M-3.09M4.35M-3.52M

Geratherm Medical Technical Analysis

Technical Analysis SentimentNegative
Last Price2.06

Price Trends

50DMA2.20Negative
100DMA2.39Negative
200DMA2.52Negative

Market Momentum

MACD-0.03Positive
RSI43.20Neutral
STOCH43.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Negative. The current price of 2.06 is below the 20-day moving average (MA) of 2.14, below the 50-day MA of 2.20, and below the 200-day MA of 2.52, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GME.

Geratherm Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:GME against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:SHLDE:SHL77OutperformEUR 48.31B22.1411.72%2.28%1.09%3.52%
DE:DRW3DE:DRW364NeutralEUR 1.93B13.1610.20%1.91%5.06%40.18%
DE:M3VDE:M3V55NeutralEUR 38.22M27.637.77%4.52%-6.92%-67.82%
DE:SBSDE:SBS54NeutralEUR 332.47M-7.84-18.69%2.19%――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DE:GMEDE:GME51NeutralEUR 11.22M-14.76-4.38%4.85%1.58%-148.73%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:GMEDE:DRW3DE:M3VDE:SBSDE:SHLDE:E8XDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:GME and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:GMEGeratherm Medical2.06-1.14-35.56%
DE:DRW3Draegerwerk AG & Co. KGaA119.0052.4378.75%
DE:M3VMeVis Medical Solutions21.00-2.90-12.13%
DE:SBSSTRATEC Biomedical27.358.0441.62%
DE:SHLSiemens Healthineers43.843.528.73%
DE:E8Xelexxion AG0.01-0.13-90.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026